CHICAGO—Telmisartan (Micardis HCT), a novel angiotensin receptor blocker (ARB), and the older ARB losartan have similar BP-lowering efficacy in hypertensive patients with diabetic nephropathy, but treatment with the new agent is associated with larger reductions in proteinuria, new findings show.